HEOR

News

Keytruda backed for 'basket' of new cancers via NHS

The UK's cost-effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of cancers based on genetic abnormalities known as microsatellite instab

News

NICE won't budge on rejection of rare disease drug

The UK's cost-effectiveness agency NICE has delivered its final verdict on Clinuvel's Scenesse, a treatment for a rare skin disorder that causes extreme sensitivity to lig

News

New HTA body pledges to ‘cut the hype’ in digital health

US non-profit the Peterson Centre on Healthcare has launched a new institute, backed with $50 million in funding, that will take a close look at the clinical benefits and

News

BMS’ Sotyktu cleared for NHS use in psoriasis

Just a few weeks after its approval in the UK, Bristol-Myers Squibb’s new oral psoriasis therapy Sotyktu has been recommended for routine NHS in England and Wales.

News

NICE not convinced yet by Mounjaro for diabetes

Eli Lilly is riding high on new data for its experimental obesity therapies, but i

News

Alarm bell rung over EU’s unified HTA plan

The EU’s joint clinical assessment (JCA) initiative has been set up to accelerate patient access to new therapies, but could end up restricting the use of new technologies